269. 化膿性無菌性関節炎・壊疽性膿皮症・アクネ症候群 ［臨床試験数：18，薬物数：22（DrugBank：11），標的遺伝子数：12，標的パスウェイ数：88］
Searched query = "Pyogenic arthritis", "Pyoderma gangrenosum", "Acne syndrome", "PAPA syndrome"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/20/2019, 11/21/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03971643 | May 16, 2019 | 11 November 2019 | Exploratory Study of IFX-1 in Subjects With Pyoderma Gangrenosum | Open Label Exploratory Phase 2a Trial to Investigate the Safety and Efficacy of IFX-1 in Treating Subjects With Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: IFX-1 | InflaRx GmbH | Innovaderm Research Inc. | Recruiting | 18 Years | N/A | All | 12 | Phase 2 | United States;Canada |
| 2 | NCT03311464 | October 27, 2017 | 30 September 2019 | A Study Assessing the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Participants in Japan | A Phase 3 Multicenter, Open-Label, Single Arm Study of the Efficacy and Safety of Adalimumab in Active Ulcer(s) of Pyoderma Gangrenosum in Subjects in Japan | Pyoderma Gangrenosum | Drug: adalimumab | AbbVie | Not recruiting | 18 Years | N/A | All | 22 | Phase 3 | Japan | |
| 3 | NCT03072953 | June 7, 2017 | 3 June 2019 | Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum | A Phase 2a, Open-label, Proof of Concept Study to Determine the Efficacy and Safety of Etrasimod (APD334) in Patients With Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: APD334 | Arena Pharmaceuticals | Not recruiting | 18 Years | 80 Years | All | 2 | Phase 2 | Australia;New Zealand | |
| 4 | NCT03137160 | May 4, 2017 | 18 December 2018 | An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum | An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Biological: Ixekizumab | Ohio State University | Eli Lilly and Company | Not recruiting | 18 Years | N/A | All | 5 | Phase 2 | United States |
| 5 | NCT02733094 | April 2016 | 11 June 2018 | Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum | Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: Secukinumab | Technische Universität München | Novartis | Recruiting | 18 Years | 75 Years | All | 5 | Phase 1/Phase 2 | Germany |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 6 | EUCTR2015-000762-65-DE | 09/07/2015 | 5 June 2017 | Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosu | Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosum | Pyoderma gangrenosum is an autoinflammatory disease, characterized by relapsing, painful ulcers of the skin. Treatment of PG is difficult. Patients suffer from long hospitalization, pain and reduced life quality. New therapeutic strategies are needed. Immunohistological staining show a high amount of IL-17 in PG. IL-17+ immune cells were located in proximity to cellular damage, indicating an involvement in the pathogenesis. Targeting IL-17 with neutralizing IL-17 antibodies seems promising. MedDRA version: 20.0 Level: PT Classification code 10037635 Term: Pyoderma gangrenosum System Organ Class: 10040785 - Skin and subcutaneous tissue disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | Trade Name: Cosentyx® Product Name: Cosentyx Product Code: EU/1/14/980/002; EU/1/14/980/003 Pharmaceutical Form: Solution and suspension for suspension for injection in pre-filled syringe | Technische Universität München, School of Medicine, represented by Dean | Authorised | Female: yes Male: yes | 7 | Phase 2;Phase 3 | Germany | |||
| 7 | NCT02366260 | February 2015 | 2 March 2015 | An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum | A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: Gevokizumab;Drug: Placebo | MedDerm Associates | XOMA (US) LLC | Recruiting | 18 Years | N/A | Both | 5 | Phase 3 | United States |
| 8 | NCT02326740 | December 2014 | 9 May 2016 | An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum | A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: gevokizumab;Drug: Placebo;Drug: gevokizumab open-label | XOMA (US) LLC | Not recruiting | 18 Years | N/A | Both | 9 | Phase 3 | United States;Australia;Canada | |
| 9 | NCT02315417 | November 2014 | 9 May 2016 | An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum | A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: gevokizumab;Drug: Placebo;Drug: gevokizumab open-label | XOMA (US) LLC | Not recruiting | 18 Years | N/A | Both | 16 | Phase 3 | United States | |
| 10 | NCT02318914 | November 2014 | 9 May 2016 | A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum | A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients With Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: gevokizumab | XOMA (US) LLC | Not recruiting | 18 Years | N/A | Both | 15 | Phase 3 | United States;Australia;Canada | |
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 11 | NCT01965613 | January 2014 | 16 December 2017 | A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum | A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum | Pyoderma Gangrenosum | Biological: Xilonix | XBiotech, Inc. | Not recruiting | 18 Years | N/A | All | 10 | Phase 2 | United States | |
| 12 | NCT01882504 | May 2013 | 15 February 2016 | Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum | An Open-label, Proof of Concept Study of Gevokizumab in the Treatment of the Acute, Inflammatory Phase of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: gevokizumab | XOMA (US) LLC | Not recruiting | 18 Years | N/A | Both | 8 | Phase 2 | United States | |
| 13 | EUCTR2011-002920-41-DE | 04/01/2012 | 10 March 2014 | Stelara® (Ustekinumab) treatment in Patients with Pyoderma gangrenosum | Open-label Trial of Stelara® (Ustekinumab) In Patients with Pyoderma gangrenosum – an open, non-placebo controlled pilot study with 10 patients. - SPG-Trial | Patients with a clinical diagnosis of Pyoderma gangrenosum MedDRA version: 14.1 Level: LLT Classification code 10037634 Term: Pyoderma gangenosum System Organ Class: 10040785 - Skin and subcutaneous tissue disorders ;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | Trade Name: Stelara Product Name: Ustekinumab Pharmaceutical Form: Solution for injection CAS Number: 815610-63-0 Other descriptive name: USTEKINUMAB Concentration unit: mg milligram(s) Concentration type: range Concentration number: 45-90 | University Hospital Tübingen | Not Recruiting | Female: yes Male: yes | Germany | |||||
| 14 | NCT01302795 | February 2011 | 10 October 2016 | Canakinumab for Pyoderma Gangrenosum | A Phase II Multi Center Open Label Pilot Study To Assess a Potential Effect of an Anti-Il-1-Beta Antagonist in the Treatment of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: Canakinumab | University of Zurich | Not recruiting | 18 Years | 99 Years | Both | 5 | Phase 2 | Switzerland | |
| 15 | EUCTR2008-008291-14-GB | 14/05/2009 | 3 September 2012 | Study of treatments in Pyoderma Gangrenosum patients - STOP GAP | Study of treatments in Pyoderma Gangrenosum patients - STOP GAP | pyoderma gangrenosum MedDRA version: 14.0 Level: LLT Classification code 10037634 Term: Pyoderma gangenosum System Organ Class: 10040785 - Skin and subcutaneous tissue disorders MedDRA version: 14.0 Level: PT Classification code 10037635 Term: Pyoderma gangrenosum System Organ Class: 10040785 - Skin and subcutaneous tissue disorders | Trade Name: Neoral soft gelatin capsules Pharmaceutical Form: Capsule, soft INN or Proposed INN: CICLOSPORIN CAS Number: 59865133 Trade Name: Neoral Oral Solution Pharmaceutical Form: Oral solution INN or Proposed INN: CICLOSPORIN CAS Number: 59865133 Product Name: Prednisolone Pharmaceutical Form: Tablet INN or Proposed INN: PREDNISOLONE CAS Number: 50248 Product Name: Prednisolone Pharmaceutical Form: Soluble tablet INN or Proposed INN: PREDNISOLONE CAS Number: 50248 Product Name: Prednisolone Pharmaceutical Form: Coated tablet INN or Proposed INN: PREDNISOLONE CAS Number: 50248 | Nottingham University Hospitals NHS Trust | Authorised | Female: yes Male: yes | United Kingdom;Ireland | |||||
| No. | TrialID | Date_ enrollement | Last_Refreshed_ on | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
| 16 | NCT00730717 | May 2009 | 19 February 2015 | Safety and Efficacy Study of Humira in Treatment of Pyoderma Gangrenosum | Multi Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum | Pyoderma Gangrenosum | Drug: Humira | Wright State University | Stanford University;Wake Forest School of Medicine | Not recruiting | 18 Years | N/A | Both | 20 | Phase 2 | United States |
| 17 | NCT00791557 | October 2008 | 19 October 2017 | Open Label Study for Adults With Pyoderma Gangrenosum and Inflammatory Bowel Disease | An Open Label Single Center Pilot Study Investigating the Clinical Response and Mechanism of Action of Infliximab in the Treatment of Adults With Inflammatory Bowel Disease Who Have Moderate to Severe Pyoderma Gangrenosum | Pyoderma Gangrenosum;Crohn's Disease;Ulcerative Colitis;Inflammatory Bowel Disease | Drug: Infliximab | University Hospitals Cleveland Medical Center | Centocor, Inc. | Not recruiting | 18 Years | 75 Years | All | 2 | N/A | United States |
| 18 | NCT00690846 | July 2007 | 20 August 2018 | Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum | A Multi-Center, Open Label Pilot Study to Determine the Safety and Efficacy of Adalimumab in the Treatment of Pyoderma Gangrenosum (HUM 04-37) | Pyoderma Gangrenosum | Drug: adalimumab | Wake Forest University Health Sciences | Not recruiting | 18 Years | N/A | All | 0 | Phase 2 | United States |